Evidence map›Paper›PMID 41399351›Full record

ArticleMaterials today. Bio2025

Engineered PD-L1-targeted multifunctional proteins with self-prolonged circulation for enhanced tumor photothermal-immunotherapy.

Shiqi Zhao, Dianlong Jia, Xiaoyun Qi, Xin Bian, Xiaoyu Song, Xiaohui Tang, Xiaoxuan Cui, Jupeng Yuan, Fei Wang, Baoqing Tian and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shiqi ZhaoDepartment of Pharmacy, Shandong Cancers Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, PR China.
Dianlong JiaState Key Laboratory of Macromolecular Drugs and Large-scale Preparation, School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, Shandong, 252059, PR China.
Xiaoyun QiState Key Laboratory of Macromolecular Drugs and Large-scale Preparation, School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, Shandong, 252059, PR China.
Xin BianDepartment of Pharmacy, Shandong Cancers Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, PR China.
Xiaoyu SongState Key Laboratory of Macromolecular Drugs and Large-scale Preparation, School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, Shandong, 252059, PR China.
Xiaohui TangDepartment of Pharmacy, Shandong Cancers Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, PR China.
Xiaoxuan CuiState Key Laboratory of Macromolecular Drugs and Large-scale Preparation, School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, Shandong, 252059, PR China.
Jupeng YuanDepartment of Pharmacy, Shandong Cancers Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, PR China.
Fei WangDepartment of Pharmacy, Shandong Cancers Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, PR China.
Baoqing TianDepartment of Pharmacy, Shandong Cancers Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, PR China.
Yiyao WangDepartment of Pharmacy, Shandong Cancers Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, PR China.
Yuchun WeiDepartment of Pharmacy, Shandong Cancers Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, PR China.
Dandan YuanDepartment of Pharmacy, Shandong Cancers Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, PR China.
Xiao SunDepartment of Pharmacy, Shandong Cancers Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, PR China.
Qing FanDepartment of Pharmacy, Shandong Cancers Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, a novel Immunoglobulin G (IgG) binding, Programmed Cell Death-Ligand 1 (PD-L1) targeting affibody, IgBD-Z

Indexed as

AffibodyImmunoglobin G-binding domainLong-acting proteinProgrammed cell death ligand 1Tumor immunotherapy

Identifiers

PMID41399351
PMCPMC12702396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.